Navigation Links
OmniSonics Appoints J. Daniel Cole Chairman of the Board
Date:9/24/2007

WILMINGTON, Mass., Sept. 24 /PRNewswire/ -- OmniSonics Medical Technologies, Inc., a leading developer of advanced medical devices for occlusive vascular disease, today announced the appointment of J. Daniel Cole as the company's new Chairman of the Board.

Mr. Cole is a founding partner with Spray Venture Partners, a venture capital firm that focuses exclusively on emerging healthcare technology companies. He brings twenty years of medical device operational experience, having served on the boards of 10 companies, two of which he started. Prior to joining Spray, Mr. Cole served as senior vice president and group president of Boston Scientific Corporation's (BSC) vascular business, a $1.2 billion group, and was also responsible for BSC's international operations. Prior to BSC, he was president and chief iperating officer of SCIMED Life Systems before the company's merger with Boston Scientific. He also held a variety of executive and general management positions at Baxter Healthcare. He currently serves on the Board of Directors of Acorn Cardiovascular, Tryton Medical, Direct Flow Medical, and Tremont Medical, and is actively involved in Kolis Scientific, PneumRx, and Thoratec Laboratories.

"We are thrilled to have Dan Cole as our new Chairman of the Board for OmniSonics," said Richard Ganz, president and CEO, OmniSonics Medical Technologies. "Over the last few years, we have been actively building a world-class team with in-depth experience in product development and commercialization. Dan's experience and leadership will be a major asset as we launch our products for vascular occlusive disease and build a word-class commercial enterprise."

"This is an exciting time to join the OmniSonics team," said J. Daniel Cole, Chairman of the Board and partner at Spray Venture Partners. "The company has assembled a management team with over 80 cumulative years of experience in medical devices and commercial operations. They have developed breakthrough technology for treating vascular occlusive disease - technology that has the chance to have a major impact on a serious health issue. The company is ready for the transition from R&D to commercialization, and I'm looking forward to being a part of that transition."

About OmniSonics Medical Technologies, Inc.

OmniSonics Medical Technologies, Inc., based in Wilmington, MA, is a venture-backed medical device company focused on developing breakthrough products for the treatment of vascular occlusive disease. The Company plans to introduce products based on its patented OmniWave(TM) Technology, the first technology capable of delivering low-power acoustic energy around the active length of a small diameter wire in a diseased blood vessel. OmniWave Technology is designed to have broad applications in vascular occlusive conditions. Clearance for use in peripheral vascular disease is expected in 2007. Additional clinical trials are planned for other indications.

Contact: Judith Rossi

978-657-9980 X502

jrossi@omnisonics.com


'/>"/>
SOURCE OmniSonics Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or ... pleased to announce that Biohaven has issued today the ... Connecticut (PRWEB) Dec 9, 2016 - Biohaven ... today that the U.S. Food and Drug Administration ("FDA") ... its drug candidate BHV-0223, an orally dissolving tablet being ...
(Date:12/8/2016)... PITTSBURGH , Dec. 8, 2016  The Board ... (PLSG), Western Pennsylvania,s only ... in leadership. In accordance with the succession plan developed ... several years, effective today, James (Jim) F. Jordan ... Executive Officer, succeeding John W. Manzetti , who ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Lajollacooks4u, San ... a banner year for team building events, new program offerings and company expansion. ... expanded earlier this year to include groups of over 30 people. Ever since, Lajollacooks4u ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... platforms, the business of innovation is taking over sports. On Thursday, December 15th ... explore how technology is disrupting the playing field at a Smart Talk session. ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):